Antivenom Market - Size, Share and Forecast (2019-2026)

SKU: DPH102 | Last Updated On: Aug 13 2019 | No. of Pages: 202 | Available Formats

On May 16, 2019, Wellcome's Trust has announced 103 USD Million program, which aims in improving the existing therapies and also supports the development of high-quality antivenoms that can treat toxins of different species of snakes.

Global Antivenom Market Overview

Antivenom is a medication, which is made from hyperimmune globulins and various other serum proteins extracted from the animals and are used to treat venomous bites and stings. They are generally recommended if there is significant toxicity or a high risk of toxicity. Antivenom is currently the mainstay of therapy for the venomous snakebites victims, which have reduced the mortality of this condition. As antivenom treatment being the only authorized treatment for snakebites with no other alternative options, it is giving opportunities for the key players to emerge in the global antivenom market.

The global antivenom market size was worth $XX billion in 2018 and is forecasted to reach $XX billion by 2026, at a CAGR of XX% during the forecast period.

Global Antivenom Market Dynamics

Global antivenom market growth is driven by increasing government initiatives to promote the development of antivenom products of high quality, increased number of snakebites victims, recent FDA approvals of antivenom products, expanded research in developing high quality and advanced antivenom products.

Increasing government initiatives for the development of high-quality antivenom products and funds from non-profit organizations is expected to boost the market over the period of forecast. For instance, in December 2015 a program was launched by WHO to evaluate the potential safety and effectiveness of current antivenom products intended for use in sub-Saharan Africa. On December 9, 2016, global snake initiative, an internationally-active non-profit organization, which is registered in Australia, has issued the position statement on the steps needed to control snakebite envenoming globally. In 2017, a Snakebite Envenoming Working Group was formed which deals with WHO road map on snakebites. This strategy mainly focuses on a 50% reduction in mortality and disability caused by snakebite envenoming by 2030. Wellcome's Trust has announced (103 USD Million) program, on May 16, 2019, aims in improving the existing therapies and also supports the development of high-quality antivenoms that can treat toxins of different species of snakes.

Increased research in the development of antivenom is expected to boost the market. For instance, the investigation of the use of small molecule inhibitors, which are currently being evaluated for their ability to neutralise the effects of enzymatic toxins is being done. They include small molecule inhibitors against enzymatic toxins and peptides, oligonucleotide-based aptamers and antibody-based biotherapeutics against both enzymatic and non-enzymatic toxins. One of the promising small molecule inhibitors is varespladib, and it may have the potential to become a broad-spectrum orally administered first line treatment for snakebite victims, or possibly an anti-PLA2-specific supplement to conventional antivenom therapy. Also, the increased research efforts on nanobodies and human antibody formats will occur over the forecast period. Other research efforts within the field of recombinant antivenom include polyclonal plantivenom which uses the phage display technology which is aimed at optimizing production rather than the stability of antivenoms.

Increase in the number of snakebites may boost the market over the period of forecast. For instance, according to WHO, 4.5–5.4 million people a year are bitten by snakes, and 1.8–2.7 million of them will develop clinical illness (envenoming) after snakebite, and the deaths may range from 81,000 to 138,000.

Recent FDA approvals are expected to drive the global anti-venom market over the forecast period. For instance, in October 2018, Silanes Laboratories has received FDA approval for Anavip, against rattlesnake bite.

However, withdrawal of antivenom products, high cost of products, stringent regulations, high cost for maintaining livestock for antivenom production are restraining the market. The high price of anti-venom products is likely to hamper the market. For instance, a typical antivenom vial costs $1,500 to $2,200, but a snake bite requires between 20 and 25 vials to get neutralized. Hence, a man bitten in the US by a venomous snake would have to spend $30,000 in pharmacy costs alone.

Global Antivenom Market Segment Analysis

Based on type, the global antivenom market is segmented into polyvalent heterologous antivenom, monovalent heterologous antivenom, homologous antivenom, and small molecule anti-toxins.

Polyvalent heterologous antivenoms segment is expected to boost the market over the period of forecast. This is owing to the presence of FDA approved antivenoms. The polyvalent anti-venoms are produced by using the hyper-immunizing venom from two or more species, and the resultant anti-venom usually contains the neutralizing antibodies against the venom of two or more species. They are generally useful in regions where there are too many poisonous species to produce monovalent anti-venoms against all of them. For instance, CROFAB® Crotalidae a polyvalent immune fab (ovine) Lyophilized Powder for Solution for Intravenous Injection is used for the management of adult and pediatric patients with North American crotalid envenomation. Antivenin (Micrurus fulvius), of Wyeth pharmaceuticals (equine origin), is indicated for the treatment of envenomation caused by the bites of Micrurus and Micruroides.

Based on species, the global antivenom market is segmented into snakes, scorpions, spiders, and others. The Snakes segment is further segmented into common krait, common cobra, russell viper, and others.

Snakes segment is expected to propel the global antivenom market. This is owing to the increased number of snakebites globally. For instance, according to WHO, more than 5 million snakebites occur worldwide each year, resulting in 2.5 million envenomations and 81,000 to 138,000 deaths. Snakebite envenoming causes as many as 400,000 amputations and other permanent disabilities. Of the 3000 or so, snake species in the world, around 600 are venomous snakes.

Scorpions segment is expected to grow at a significant rate in the market over the period of forecast. This is owing to the FDA approvals. For instance, on August 4, 2011, US FDA for the first time has approved antivenom specifically for the treatment of Centruroides scorpion stings.

Based on the mode of action, the global antivenom market is segmented into cytotoxic, neurotoxic, haemotoxic, cardiotoxic, myotoxic, and others.

Based on end-users, the global Antivenom market is segmented into hospitals, clinics, ambulatory surgical centers, and others. The hospital's segment is expected to hold a significant share in the market. This is owing to the easy availability and accessibility of antivenoms in the hospitals, which is the mainstay of treatment for snakebites. However, ambulatory surgical centers segment is expected to grow high over the forecast period by 2.1X times by 2019.

Global Antivenom Market Geographical Analysis

North America is dominating the global antivenom market in 2018 and estimated to hold the largest market size over the forecast period (2019-2026). This is owing to the abundance of snake population in the region, rising number of snakebites, FDA approvals and government initiatives for the development of high-quality antivenoms.

For instance, the US has about 20 species of venomous snakes, that includes 16 species of rattlesnakes, 2 species of coral snakes, one species of cottonmouth (or water moccasin), and one species of the copperhead. Also, atleast one species of venomous snake is found in every state except Hawaii. Thus the presence of abundant snake population may lead to an increased number of snakebites over the period of forecast.

FDA approvals for the antivenoms of North American inhabitant snakes are expected to boost the market. For instance, Rare Disease Therapeutics has announced FDA approval of Crotalidae Immune F(ab')2 (Equine), an equine-derived antivenin for the treatment of North American rattlesnake bites in adult and pediatric patients.

The increasing number of snakebites is expected to boost the market. For instance, according to CDC in 2013, it has been estimated that 7,000–8,000 people per year have venomous snake bites in the US, and about five of those people die.

Global Antivenom Market Competitive Landscape

Some of the major players in the Global antivenom market are Pfizer, Merck, Haffkine Bio-Pharmaceutical Corporation Ltd, CSL Behring,Bharat Serums and Vaccines Ltd., Rare Therapeutics, Incepta vaccines Ltd and Vins Bioproducts Limited.

The key players are adopting various strategies such as product launches, mergers & acquisitions, partnerships, and collaborations, which are contributing to the growth of the Antivenom market globally. For instance,

FDA has extended the expiration date on Antivenin (Micrurus fulvius) (Equine Origin), from January 31, 2019, to January 31, 2020 for Coral Snake Antivenom product manufactured by Wyeth Pharmaceuticals, which is now a wholly-owned subsidiary of Pfizer, Inc.

In September 2018, BTG plc. announced the FDA approval for updating the shelf life of CroFab Crotalidae Polyvalent Immune Fab (Ovine) to 60 months.

Why Purchase the Report?

  • Visualize the composition of the global antivenom market in terms of various type, species type, mode of action and end-users highlighting the critical commercial assets and players.
  • Identify commercial opportunities in global antivenom market by analyzing trends and co-development deals.
  • Excel data sheet with thousands of data points of global antivenom market-level 4/5 segmentation.
  • A PDF report with the most relevant analysis cogently put together after exhaustive qualitative interviews and in-depth market study.
  • Product mapping in excel for the key product of all major market players

Target Audience

  • Service Providers/ Buyers
  • Industry Investors/Investment Bankers
  • Education & Research Institutes
  • Research Professionals
  • Emerging Companies
  • Manufacturers

Global Antivenom Market

  1. Global Antivenom Market Methodology and Scope

    1. Research Objective and Scope of the Report
    2. Research Methodology
  2. Global Antivenom Market – Market Definition and Overview

  3. Global Antivenom Market – Executive Summary

    1. Market Snippet by Type
  4. Global Antivenom Market Dynamics

    1. Market Impacting Factors
    2. Drivers
      1. increasing government initiatives to promote the development of antivenom products of high quality
      2. Increasing number of snake bites
    3. Restraints
      1. High cost of anti venom products
    4. Opportunity
    5. Impact Analysis
  5. Global Antivenom Market – Industry Analysis

    1. Porter's Five Forces Analysis
    2. Regulatory Analysis
    3. Supply Chain Analysis
    4. Pricing Analysis
  6. Global Antivenom Market – By Type

    1. Introduction
      1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type Segment
      2. Market Attractiveness Index, By Type
    2. Polyvalent heterologous antivenom *
      1. Introduction
      2. Market Size Analysis, US$ Mn, 2016-2025 and Y-o-Y Growth Analysis (%), 2018-2026
    3. Monovalent heterologous antivenom
    4. Homologous antivenom
    5. Small molecule anti-toxins
  7. Global Antivenom  Market – By Species

    1. Introduction
      1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Species  Segment
      2. Market Attractiveness Index, By Species Segment
    2. Snakes*
      1. Introduction
      2. Market Size Analysis, US$ Mn, 2016-2025 and Y-o-Y Growth Analysis (%), 2018-2026
    3. Scorpions
    4. Spiders
    5. Others
  8. Global Antivenom Market – By Mode of action

    1. Introduction
      1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Mode of action segment
      2. Market Attractiveness Index, By mode of action segment
    2. Cytotoxic *
      1. Introduction
      2. Market Size Analysis, US$ Mn, 2016-2025 and Y-o-Y Growth Analysis (%), 2018-2026
    3. Neurotoxic
    4. Haemotoxic
    5. Cardiotoxic
    6. Myotoxic
    7. Others
  9. Global Antivenom Market – By End-User

    1. Introduction
      1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End-User Segment
      2. Market Attractiveness Index, By End-User Segment
    2. Hospitals*
      1. Introduction
      2. Market Size Analysis, US$ Mn, 2016-2025 and Y-o-Y Growth Analysis (%), 2018-2026
    3. Clinics
    4. Ambulatory surgical Centers
  10. Global Antivenom Market - By Region

    1. Introduction
      1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Region
      2. Market Attractiveness Index, By Region
    2. North America
      1. Introduction
      2. Key Region-Specific Dynamics
      3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
      4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Species
      5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Mode of action
      6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End-User
      7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
        1. The U.S.
        2. Canada
        3. Mexico
    3. Europe
      1. Introduction
      2. Key Region-Specific Dynamics
      3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Class
      4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Formulation type
      5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End-User
      6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
        1. Germany
        2. The U.K.
        3. France
        4. Italy
        5. Spain
        6. Rest of Europe
    4. South America
      1. Introduction
      2. Key Region-Specific Dynamics
      3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Class
      4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Formulation type
      5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End-User
      6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
        1. Brazil
        2. Argentina
        3. Rest of South America
    5. Asia Pacific
      1. Introduction
      2. Key Region-Specific Dynamics
      3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Class
      4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Formulation type
      5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End-User
      6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
        1. China
        2. India
        3. Japan
        4. Australia
        5. Rest of Asia Pacific
    6. The Middle East and Africa
      1. Introduction
      2. Key Region-Specific Dynamics
      3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Class
      4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Formulation type
      5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End-User
  11. Global Antivenom Market Competitive Landscape

    1. Competitive Scenario
    2. Market Positioning/Share Analysis
    3. Mergers and Acquisitions Analysis
  12. Global Antivenom Market Company Profiles

    1. Pfizer *
      1. Company Overview
      2. Product Portfolio and Description
      3. Key Highlights
      4. Financial Overview
    2. Merck
    3. Haffkine Bio-Pharmaceutical Corporation Ltd
    4. CSL Behring
    5. Bharat Serums and Vaccines Ltd
    6. Rare Therapeutics
    7. Incepta vaccines Ltd
    8. Vins Bioproducts Limited
  13. Global Antivenom Market – Premium Insights

  14. Global Antivenom Market – DataM

    1. Appendix
    2. About Us and Services
    3. Contact Us

LIST OF TABLES

TABLE 01

GLOBAL ANTIVENOM MARKET VALUE, BY TYPE , 2018,2022 & 2026 ($ MILLION)

TABLE 02

GLOBAL ANTIVENOM MARKET VALUE, BY SPECIES TYPE, 2018,2022 & 2026 ($ MILLION)

TABLE 03

GLOBAL ANTIVENOM MARKET VALUE, BY MODE OF ACTION, 2018,2022 & 2026 ($ MILLION)

TABLE 04

GLOBAL ANTIVENOM MARKET VALUE, BY END-USERS, 2018,2022 & 2026 ($ MILLION)

TABLE 05

GLOBAL ANTIVENOM MARKET VALUE, BY REGION , 2018,2022 & 2026 ($ MILLION)

TABLE 06

GLOBAL ANTIVENOM MARKET VALUE, BY TYPE , 2018,2022 & 2026 ($ MILLION)

TABLE 07

GLOBAL ANTIVENOM MARKET VALUE, BY TYPE, 2017-2026 ($ MILLION)

TABLE 08

GLOBAL ANTIVENOM MARKET VALUE, BY SPECIES TYPE, 2018,2022 & 2026 ($ MILLION)

TABLE 09

GLOBAL ANTIVENOM MARKET VALUE, BY SPECIES TYPE, 2017-2026 ($ MILLION)

TABLE 10

GLOBAL ANTIVENOM MARKET VALUE, BY MODE OF ACTION, 2018,2022 & 2026 ($ MILLION)

TABLE 11

GLOBAL ANTIVENOM MARKET VALUE, BY MODE OF ACTION, 2017-2026 ($ MILLION)

TABLE 12

GLOBAL ANTIVENOM MARKET VALUE, BY END-USERS, 2018,2022 & 2026 ($ MILLION)

TABLE 13

GLOBAL ANTIVENOM MARKET VALUE, BY END-USERS, 2017-2026 ($ MILLION)

TABLE 14

GLOBAL ANTIVENOM MARKET VALUE, BY REGION , 2018,2022 & 2026 ($ MILLION)

TABLE 15

GLOBAL ANTIVENOM MARKET VALUE, BY REGION, 2017-2026 ($ MILLION)

TABLE 16

NORTH AMERICA ANTIVENOM MARKET VALUE, BY TYPE, 2017-2026 ($ MILLION)

TABLE 17

NORTH AMERICA ANTIVENOM MARKET VALUE, BY SPECIES TYPE, 2017-2026 ($ MILLION)

TABLE 18

NORTH AMERICA ANTIVENOM MARKET VALUE, BY MODE OF ACTION, 2017-2026 ($ MILLION)

TABLE 19

NORTH AMERICA ANTIVENOM MARKET VALUE, BY END-USERS, 2017-2026 ($ MILLION)

TABLE 20

NORTH AMERICA ANTIVENOM MARKET VALUE, BY REGION, 2017-2026 ($ MILLION)

TABLE 21

SOUTH AMERICA ANTIVENOM MARKET VALUE, BY TYPE, 2017-2026 ($ MILLION)

TABLE 22

SOUTH AMERICA ANTIVENOM MARKET VALUE, BY SPECIES TYPE, 2017-2026 ($ MILLION)

TABLE 23

SOUTH AMERICA ANTIVENOM MARKET VALUE, BY MODE OF ACTION, 2017-2026 ($ MILLION)

TABLE 24

SOUTH AMERICA ANTIVENOM MARKET VALUE, BY END-USERS, 2017-2026 ($ MILLION)

TABLE 25

SOUTH AMERICA ANTIVENOM MARKET VALUE, BY REGION, 2017-2026 ($ MILLION)

TABLE 26

EUROPE ANTIVENOM MARKET VALUE, BY TYPE, 2017-2026 ($ MILLION)

TABLE 27

EUROPE ANTIVENOM MARKET VALUE, BY SPECIES TYPE, 2017-2026 ($ MILLION)

TABLE 28

EUROPE ANTIVENOM MARKET VALUE, BY MODE OF ACTION, 2017-2026 ($ MILLION)

TABLE 29

EUROPE ANTIVENOM MARKET VALUE, BY END-USERS, 2017-2026 ($ MILLION)

TABLE 30

EUROPE ANTIVENOM MARKET VALUE, BY REGION, 2017-2026 ($ MILLION)

TABLE 31

ASIA-PACIFIC ANTIVENOM MARKET VALUE, BY TYPE, 2017-2026 ($ MILLION)

TABLE 32

ASIA-PACIFIC ANTIVENOM MARKET VALUE, BY SPECIES TYPE, 2017-2026 ($ MILLION)

TABLE 33

ASIA-PACIFIC ANTIVENOM MARKET VALUE, BY MODE OF ACTION, 2017-2026 ($ MILLION)

TABLE 34

ASIA-PACIFIC ANTIVENOM MARKET VALUE, BY END-USERS, 2017-2026 ($ MILLION)

TABLE 35

ASIA-PACIFIC ANTIVENOM MARKET VALUE, BY REGION, 2017-2026 ($ MILLION)

TABLE 36

MIDDLE EAST & AFRICA ANTIVENOM MARKET VALUE, BY TYPE, 2017-2026 ($ MILLION)

TABLE 37

MIDDLE EAST & AFRICA ANTIVENOM MARKET VALUE, BY SPECIES TYPE, 2017-2026 ($ MILLION)

TABLE 38

MIDDLE EAST & AFRICA ANTIVENOM MARKET VALUE, BY MODE OF ACTION, 2017-2026 ($ MILLION)

TABLE 39

MIDDLE EAST & AFRICA ANTIVENOM MARKET VALUE, BY END-USERS, 2017-2026 ($ MILLION)

TABLE 40

MIDDLE EAST & AFRICA ANTIVENOM MARKET VALUE, BY REGION, 2017-2026 ($ MILLION)

TABLE 41

PFIZER: OVERVIEW

TABLE 42

PFIZER: PRODUCT PORTFOLIO

TABLE 43

PFIZER: KEY DEVELOPMENTS

TABLE 44

MERCK: OVERVIEW

TABLE 45

MERCK: PRODUCT PORTFOLIO

TABLE 46

MERCK: KEY DEVELOPMENTS

TABLE 47

CSL BEHRING: OVERVIEW

TABLE 48

CSL BEHRING: PRODUCT PORTFOLIO

TABLE 49

CSL BEHRING: KEY DEVELOPMENTS

TABLE 50

HAFFKINE BIO-PHARMACEUTICAL CORPORATION LTD: OVERVIEW

TABLE 51

HAFFKINE BIO-PHARMACEUTICAL CORPORATION LTD: PRODUCT PORTFOLIO

TABLE 52

HAFFKINE BIO-PHARMACEUTICAL CORPORATION LTD: KEY DEVELOPMENTS

TABLE 53

BHARAT SERUMS AND VACCINES LTD. : OVERVIEW

TABLE 54

BHARAT SERUMS AND VACCINES LTD. : PRODUCT PORTFOLIO

TABLE 55

BHARAT SERUMS AND VACCINES LTD. : KEY DEVELOPMENTS

TABLE 56

RARE THERAPEUTICS : OVERVIEW

TABLE 57

RARE THERAPEUTICS : PRODUCT PORTFOLIO

TABLE 58

RARE THERAPEUTICS : KEY DEVELOPMENTS

TABLE 59

INCEPTA VACCINES LTD : OVERVIEW

TABLE 60

INCEPTA VACCINES LTD : PRODUCT PORTFOLIO

TABLE 61

INCEPTA VACCINES LTD : KEY DEVELOPMENTS

TABLE 62

VINS BIOPRODUCTS LIMITED: OVERVIEW

TABLE 63

VINS BIOPRODUCTS LIMITED: PRODUCT PORTFOLIO

TABLE 64

VINS BIOPRODUCTS LIMITED: KEY DEVELOPMENTS

LIST OF FIGURES

FIGURE 01

GLOBAL ANTIVENOM MARKET SHARE, BY TYPE, 2018 & 2026 (%)

FIGURE 02

GLOBAL ANTIVENOM MARKET SHARE, BY SPECIES TYPE, 2018 & 2026 (%)

FIGURE 03

GLOBAL ANTIVENOM MARKET SHARE, BY MODE OF ACTION, 2018 & 2026 (%)

FIGURE 04

GLOBAL ANTIVENOM MARKET SHARE, BY END-USERS, 2018 & 2026 (%)

FIGURE 05

GLOBAL ANTIVENOM MARKET SHARE, BY REGION, 2018 & 2026 (%)

FIGURE 06

GLOBAL ANTIVENOM MARKET SHARE, BY COUNTRY, 2018 & 2026 (%)

FIGURE 07

GLOBAL ANTIVENOM MARKET VALUE, 2017-2026 ($ MILLION)

FIGURE 08

GLOBAL ANTIVENOM MARKET Y-O-Y GROWTH, BY TYPE , 2018-2026 (%)

FIGURE 09

POLYVALENT HETEROLOGOUS ANTIVENOM: GLOBAL ANTIVENOM MARKET VALUE, 2017-2026 ($ MILLION)

FIGURE 10

MONOVALENT HETEROLOGOUS ANTIVENOM: GLOBAL ANTIVENOM MARKET VALUE, 2017-2026 ($ MILLION)

FIGURE 11

GLOBAL ANTIVENOM MARKET Y-O-Y GROWTH, BY SPECIES TYPE, 2018-2026 (%)

FIGURE 12

SNAKES: GLOBAL ANTIVENOM MARKET VALUE, 2017-2026 ($ MILLION)

FIGURE 13

SCORPIONS: GLOBAL ANTIVENOM MARKET VALUE, 2017-2026 ($ MILLION)

FIGURE 14

SPIDERS: GLOBAL ANTIVENOM MARKET VALUE, 2017-2026 ($ MILLION)

FIGURE 15

OTHERS: GLOBAL ANTIVENOM MARKET VALUE, 2017-2026 ($ MILLION)

FIGURE 16

GLOBAL ANTIVENOM MARKET Y-O-Y GROWTH, BY MODE OF ACTION, 2018-2026 (%)

FIGURE 17

CYTOTOXIC: GLOBAL ANTIVENOM MARKET VALUE, 2017-2026 ($ MILLION)

FIGURE 18

NEUROTOXIC: GLOBAL ANTIVENOM MARKET VALUE, 2017-2026 ($ MILLION)

FIGURE 19

CARDIOTOXIC: GLOBAL ANTIVENOM MARKET VALUE, 2017-2026 ($ MILLION)

FIGURE 20

GLOBAL ANTIVENOM MARKET Y-O-Y GROWTH, BY END-USERS, 2018-2026 (%)

FIGURE 21

HOSPITALS: GLOBAL ANTIVENOM MARKET VALUE, 2017-2026 ($ MILLION)

FIGURE 22

GLOBAL ANTIVENOM MARKET Y-O-Y GROWTH, BY REGION, 2018-2026 (%)

FIGURE 23

GLOBAL ANTIVENOM MARKET Y-O-Y GROWTH, BY COUNTRY, 2018-2026 (%)

FIGURE 24

NORTH AMERICA ANTIVENOM MARKET VALUE, 2017-2026 ($ MILLION)

FIGURE 25

NORTH AMERICA ANTIVENOM MARKET SHARE, BY TYPE, 2018 & 2026 (%)

FIGURE 26

NORTH AMERICA ANTIVENOM MARKET SHARE, BY SPECIES TYPE, 2018 & 2026 (%)

FIGURE 27

NORTH AMERICA ANTIVENOM MARKET SHARE, BY MODE OF ACTION, 2018 & 2026 (%)

FIGURE 28

NORTH AMERICA ANTIVENOM MARKET SHARE, BY END-USERS, 2018 & 2026 (%)

FIGURE 29

NORTH AMERICA ANTIVENOM MARKET SHARE, BY REGION, 2018 & 2026 (%)

FIGURE 30

SOUTH AMERICA ANTIVENOM MARKET VALUE, 2017-2026 ($ MILLION)

FIGURE 31

SOUTH AMERICA ANTIVENOM MARKET SHARE, BY TYPE, 2018 & 2026 (%)

FIGURE 32

SOUTH AMERICA ANTIVENOM MARKET SHARE, BY SPECIES TYPE, 2018 & 2026 (%)

FIGURE 33

SOUTH AMERICA ANTIVENOM MARKET SHARE, BY MODE OF ACTION, 2018 & 2026 (%)

FIGURE 34

SOUTH AMERICA ANTIVENOM MARKET SHARE, BY END-USERS, 2018 & 2026 (%)

FIGURE 35

SOUTH AMERICA ANTIVENOM MARKET SHARE, BY REGION, 2018 & 2026 (%)

FIGURE 36

EUROPE ANTIVENOM MARKET VALUE, 2017-2026 ($ MILLION)

FIGURE 37

EUROPE ANTIVENOM MARKET SHARE, BY TYPE, 2018 & 2026 (%)

FIGURE 38

EUROPE ANTIVENOM MARKET SHARE, BY SPECIES TYPE, 2018 & 2026 (%)

FIGURE 39

EUROPE ANTIVENOM MARKET SHARE, BY MODE OF ACTION, 2018 & 2026 (%)

FIGURE 40

EUROPE ANTIVENOM MARKET SHARE, BY END-USERS, 2018 & 2026 (%)

FIGURE 41

EUROPE ANTIVENOM MARKET SHARE, BY REGION, 2018 & 2026 (%)

FIGURE 42

ASIA-PACIFIC ANTIVENOM MARKET VALUE, 2017-2026 ($ MILLION)

FIGURE 43

ASIA-PACIFIC ANTIVENOM MARKET SHARE, BY TYPE, 2018 & 2026 (%)

FIGURE 44

ASIA-PACIFIC ANTIVENOM MARKET SHARE, BY SPECIES TYPE, 2018 & 2026 (%)

FIGURE 45

ASIA-PACIFIC ANTIVENOM MARKET SHARE, BY MODE OF ACTION, 2018 & 2026 (%)

FIGURE 46

ASIA-PACIFIC ANTIVENOM MARKET SHARE, BY END-USERS, 2018 & 2026 (%)

FIGURE 47

ASIA-PACIFIC ANTIVENOM MARKET SHARE, BY REGION, 2018 & 2026 (%)

FIGURE 48

MIDDLE EAST & AFRICA ANTIVENOM MARKET VALUE, 2017-2026 ($ MILLION)

FIGURE 49

MIDDLE EAST & AFRICA ANTIVENOM MARKET SHARE, BY TYPE, 2018 & 2026 (%)

FIGURE 50

MIDDLE EAST & AFRICA ANTIVENOM MARKET SHARE, BY SPECIES TYPE, 2018 & 2026 (%)

FIGURE 51

MIDDLE EAST & AFRICA ANTIVENOM MARKET SHARE, BY MODE OF ACTION, 2018 & 2026 (%)

FIGURE 52

MIDDLE EAST & AFRICA ANTIVENOM MARKET SHARE, BY END-USERS, 2018 & 2026 (%)

FIGURE 53

MIDDLE EAST & AFRICA ANTIVENOM MARKET SHARE, BY REGION, 2018 & 2026 (%)

FIGURE 54

PFIZER: FINANCIALS

FIGURE 55

MERCK: FINANCIALS

FIGURE 56

CSL BEHRING: FINANCIALS

FIGURE 57

HAFFKINE BIO-PHARMACEUTICAL CORPORATION LTD: FINANCIALS

FIGURE 58

BHARAT SERUMS AND VACCINES LTD.: FINANCIALS

FIGURE 59

RARE THERAPEUTICS: FINANCIALS

FIGURE 60

INCEPTA VACCINES LTD : FINANCIALS

FIGURE 61

VINS BIOPRODUCTS LIMITED: FINANCIALS

Did not find what you were looking for?Every 7 out of 10 customers request tailored reports. Get yours today!
We collate your requirements.
Our global research team is put into action.
We deliver, and make sure your endeavour is a success!

Buy This Report



Get your FREE SAMPLE PROPOSAL with a single click!